View on GitHub

Updated current and draft version of the database with FDA oncology approvals from May and June, thus far, 2025.

Database content updates

Added entries:

  • (FDA) Taletrectinib for the treatment of patients with ROS1-positive non-small cell lung cancer.
  • (FDA) Telisotuzumab vedotin for the treatment of patients with high c-Met protein overexpression non-squamous non-small cell lung cancer.
  • (FDA) Avutometinib in combination with defactinib for the treatment of patients with KRAS-mutant low-grade serous ovarian cancer (G12C, G12V).